dc.contributor.author |
Ramirez U. |
|
dc.contributor.author |
Nikonova A. |
|
dc.contributor.author |
Liu H. |
|
dc.contributor.author |
Pecherskaya A. |
|
dc.contributor.author |
Lawrence S. |
|
dc.contributor.author |
Serebriiskii I. |
|
dc.contributor.author |
Zhou Y. |
|
dc.contributor.author |
Robinson M. |
|
dc.contributor.author |
Einarson M. |
|
dc.contributor.author |
Golemis E. |
|
dc.contributor.author |
Jaffe E. |
|
dc.date.accessioned |
2018-09-18T20:36:35Z |
|
dc.date.available |
2018-09-18T20:36:35Z |
|
dc.date.issued |
2015 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/141653 |
|
dc.description.abstract |
© Ramirez et al. 2015. Background: Overexpression or mutation of the epidermal growth factor receptor (EGFR) potently enhances the growth of many solid tumors. Tumor cells frequently display resistance to mechanistically-distinct EGFR-directed therapeutic agents, making it valuable to develop therapeutics that work by additional mechanisms. Current EGFR-targeting therapeutics include antibodies targeting the extracellular domains, and small molecules inhibiting the intracellular kinase domain. Recent studies have identified a novel prone extracellular tetrameric EGFR configuration, which we identify as a potential target for drug discovery. Methods: Our focus is on the prone EGFR tetramer, which contains a novel protein-protein interface involving extracellular domain III. This EGFR tetramer is computationally targeted for stabilization by small molecule ligand binding. This study performed virtual screening of a Life Chemicals, Inc. small molecule library of 345,232 drug-like compounds against a molecular dynamics simulation of protein-protein interfaces distinct to the novel tetramer. One hundred nine chemically diverse candidate molecules were selected and evaluated using a cell-based high-content imaging screen that directly assessed induced internalization of the EGFR effector protein Grb2. Positive hits were further evaluated for influence on phosphorylation of EGFR and its effector ERK1/2. Results: Fourteen hit compounds affected internalization of Grb2, an adaptor responsive to EGFR activation. Most hits had limited effect on cell viability, and minimally influenced EGFR and ERK1/2 phosphorylation. Docked hit compound poses generally include Arg270 or neighboring residues, which are also involved in binding the effective therapeutic cetuximab, guiding further chemical optimization. Conclusions: These data suggest that the EGFR tetrameric configuration offers a novel cancer drug target. |
|
dc.subject |
Epidermal growth factor receptor |
|
dc.subject |
Extracellular domain |
|
dc.subject |
Grb2 |
|
dc.subject |
Protein multimerization |
|
dc.title |
Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
1 |
|
dc.relation.ispartofseries-volume |
15 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.source.id |
SCOPUS-2015-15-1-SID84930666116 |
|